ITALIAN JOURNAL OF PUBLIC HEALTH Aspetti economici ... - Ijph.it

IJPH - Year 8, Volume 7, Number 3, Suppl. 2, 2010
I T A L I A N J O U R N A L O F P U B L I C H E A L T H
minor numero di viaggi) [22].
Alla luce della considerazioni sopra esplicitate,
appare opportuno estendere l’impiego del
nuovo regime all’interno del territorio nazionale
in quanto esso, oltre a presentare risultati clinici
di prim’ordine, comporta notevoli vantaggi
economici associati prevalentemente alla
possibilità di gestione domiciliare della nuova
terapia da parte dei pazienti.
Bibliografia
1) Giuliani G, Lucioni C, Mazzi S, De Carli C, Jamieson C.
Valutazione di convenienza economica comparata tra un
farmaco orale (capecitabina) e una terapia parenterale a base di
5-FU (regime Mayo) nel trattamento del tumore del colon-retto
metastatizzato. Pharmacoeconomics, Italian Research Articles
2002;4 (1):13-38.
2) La Torre G, Chiaradia G, de Waure C, Nicolotti N, Monteduro
A, Ricciardi W. Report HTA del vaccino quadrivalente anti-HPV
Gardasil. Ital J Public Health 2009;6(suppl 2).
3) Belovich D, Hux M, Douglas P, Maroun JA, Sommer
N. Cost-effectiveness of capecitabine in combination with
oxaliplatin (XELOX) compared with FOLFOX for the treatment
of metastatic colorectal cancer: A Canadian evaluation. J Clin
Oncol 2009;27 (suppl; abstract e17502).
4) Garrison L, Guiliani G, Ducournau P, et al. Cost analysis of
XELOX vs. FOLFOX-4 ± Avastin (bev) in metastatic colorectal
cancer (MCRC) from an Italian hospital perspective. ISPOR
Europe 2007b, 20–23 October, Dublin, Ireland, Abstr PCN38.
5) Garrison L, Cassidy J, Saleh M, et al. Cost comparison
of XELOX compared to FOLFOX4 with or without Avastin
(bev) in metastatic colorectal cancer. J Clin Oncol 2007a
ASCO Annual Meeting Proceedings Part I; 25(18S) June 20
Suppl:4074.
6) Perrocheau G, Bennouna J, Ducreaux M, et al. Costminimization
analysis of a phase III study of capecitabine
+ oxaliplatin (XELOX) vs infusional 5-FU/LV + oxaliplatino
(FOLFOX-6) as first-line treatment for metastatic colorectal
cancer (MCRC) in the French setting. J Clin Oncol 2007
ASCO Annual Meeting Proceedings Part I; 25(18S) June 20
Suppl:4083.
7) Jansman FGA, Postma MJ, van Hartskamp D, Willemse PHB,
Brouwers JRBJ. Cost-benefit analysis of capecitabine versus
5-fluorouracil/leucovorin in the treatment of colorectal cancer
in the Netherlands. ClinTher 2004;26(4):579-89.
8) Cassidy J, Douillard J-Y, Twelves C, et al. Pharmacoeconomic
analysis of adjuvant capecitabine vs intravenous 5 FU/LV in
Dukes’ C colon cancer: X-ACT trial. BJC 2006;94:1122-29.
9) Conroy T, Hebbar M, Bennouna J, et al. Quality-of-life
findings from a randomised phase-III study of XELOX vs
FOLFOX-6 in metastatic colorectal cancer. BJC 2010;102:59-67.
10) Manidakis N, Fragoulakis V, Pectasides D, Fountzilas G.
XELOX vs FOLFOX 6 as an adjuvant treatment in colorectal
cancer: an economic analysis. Curr Med Res and Op
2009;25(3):797-805.
11) Brandi G, Di Cicilia R, Di Battista M, et al. Capecitabine
(CAP) based regimens vs infusional 5-FU/FA in metastatic
colorectal cancer cost/effectiveness: the differences across
the atlantic Ocean. Ann Oncol 2008; 19 (suppl 9). Disponibile
online al sito: http://annonc.oxfordjournals.org/content/19/
suppl_9/ix63.full.pdf+html (Ultimo accesso: 15.06.2010).
12) Antonuzzo L, Negrini C, Gasperoni S, et al.
Pharmacoeconomic analysis of adjuvant chemotherapy with
fluoropymidine in colon cancer. Ann Oncol 2008; 19 (suppl
9). Disponibile online al sito: http://annonc.oxfordjournals.
org/content/19/suppl_9/ix63.full.pdf+html (Ultimo accesso:
15.06.2010).
13) Chu E, Cartwright T H. Pharmacoeconomic benefits of
capecitabine-based chemotherapy in metastatic colorectal
cancer. J Clin Oncol 2008; 26(13): 2224-6.
14) Shiroiwa T, Furkuda T, Tzutani K. Health utility scores of
colorectal cancer based on societal preference in Japan. Qual
Life Res 2009;18:1095–103.
15) Lopatriello S, Amoroso D, Donati S, et al The CAP-CR
study: direct medical costs in Italian metastatic colorectal
cancer patients on first line infusional 5-Fluorouracil or oral
capecitabine. EJC 2008, 44: 2615-22.
16) Araújo DV, Cirrincione A. Cost of colorectal cancer
treatment in elderly patients. BJGG 2006;9(1): 72-81.
17) Lopatriello S, Negrini C, Amoroso D, Donati S. Gestione
del paziente affetto da tumore del colon-retto metastatico:
conseguenze economiche dei diversi percorsi terapeutici.
Farmacoeconomia e percorsi terapeutici 2009;10(3): 141-6.
18) Shiroiwa T, Furkuda T, Tzutani K. Cost-effectiveness
analysis of XELOX for metastatic colorectal cancer based on
the NO 16996 and NO 16967 trials. BJC 2009;101:12-8.
19) Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness
analysis of bevacizumab combined with chemotherapy for
the treatment of metastatic colorectal cancer in Japan. Clin
Ther 2007;29(10): 2256-67.
20) Saltz L B, Clarke S, Diaz-Rubio E, et al. Bevacizumab in
combination with oxaliplatin-based chemotherapy as first-line
therapy in metastatic colorectal cancer: a ranzomized phase III
study. J Clin Oncol 2008;26: 2013-19.
21) Rothenberg M L, Cox J V, Butts C, et al. Capecitabine
plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus
oxaliplatin (FOLFOX-4) as second line therapy in metastatic
colorectal cancer: a randomized phase III noninferiority study.
Ann Oncol 2008;19:1720-6.
22) Di Costanzo F, Antonuzzo L, Rotella V, Negrini C. Analisi
farmacoeconomica in pazienti trattati con capecitabina in
terapia adiuvante. Clin Prac 2008; 10:17-25.
23) Goerner M, Riemer-Hommel P. Economic impact of
Alternative Adjuvant Chemoterapy Regimens for Stage III
Colon Cancer. Onkologie 2009; 32:647-52.
C A P I T O L O 5 S 6 9